We found a match
Your institution may have rights to this item. Sign in to continue.
- Title
A phase I study of ifosfamide given on alternate days to treat children with brain tumors.
- Authors
Pratt, Charles B.; Douglass, Edwin C.; Heideman, Richard; Avery, Loraine; Kellie, Stewart J.; Kovnar, Edward H.; Kun, Larry; Pratt, C B; Douglass, E C; Kovnar, E H; Heideman, R; Kun, L; Avery, L; Kellie, S J
- Abstract
<bold>Background: </bold>Ifosfamide with Mesna, given every other day over a 5-day period, was evaluated in 20 children with recurrent or progressive primary brain tumors.<bold>Methods: </bold>The patients were assigned to dosage cohorts separated on the basis of prior exposure to cisplatin (n = 10) or the absence of such exposure (n = 10). The initial dose in each treatment arm was 2133 mg/m2 every other day for three doses, which represented 80% of the total dose delivered in our prior study of ifosfamide given daily over 5 days. The dose was escalated by 20% in each of the two subsequent cohorts (2560 mg/m2 and 3072 mg/m2 every other day for three doses).<bold>Results: </bold>The hematologic toxicity was dose limiting. Prior exposure to cisplatin did not seem to increase the hematologic toxicity. The most frequent and significant metabolic disturbance was hyponatremia, resulting in self-limited seizure activity in three patients. This complication was prevented in subsequent patients by changing the post-ifosfamide hydration fluids from 5% dextrose in quarter normal saline to 5% dextrose in normal saline.<bold>Conclusions: </bold>Although no child achieved a complete response, the activity of ifosfamide was demonstrated for a variety of tumors. The recommended dose of ifosfamide in a Phase II study for brain tumors is 3000 mg/m2 given with Mesna every other day for three doses.
- Publication
Cancer (0008543X), 1993, Vol 71, Issue 11, p3666
- ISSN
0008-543X
- Publication type
journal article
- DOI
10.1002/1097-0142(19930601)71:11<3666::AID-CNCR2820711132>3.0.CO;2-E